Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Belite Bio Finalizes Phase 3 Clinical Trial Plans For Advanced Dry AMD Treatment With Tinlarebant (LBS-008)

Tinlarebant (a/k/a LBS-008) is Belite Bio's orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry
byBill Haddad
November 18, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD)
  • There are currently no approved treatments for STGD1 and Dry AMD
  • Currently, a 2-year Phase 2 study in adolescent STGD1 patients is ongoing and a global Phase 3 study in adolescent STGD1 patients (the “DRAGON” study) is recruiting subjects
  • 12-month interim data from the ongoing Phase 2 STGD1 study continues to show halting or slowing of lesion growth
  • Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease Designation in the U.S., and Orphan Drug Designation in both the U.S. and Europe for STGD1
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval For Opdivo With Chemotherapy As Neoadjuvant Treatment Of Resectable Non-Small Cell Lung Cancer At High Risk Of Recurrence In Patients With Tumor Cell PD-L1 Expression

By Happy Mohamed
May 26, 8:12 AM
Recommendation based on results from the Phase 3 CheckMate -816 trial, in which Opdivo with chemotherapy demonstrated improved event-free survival and pathologic complete response compared to chemotherapy alone

BMY